AGTC Applied Genetic Technologies Corp

Price (delayed)

$3.34

Market cap

$142.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.17

Enterprise value

$67.86M

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a ...

Highlights
Applied Genetic Technologies's equity has soared by 134% from the previous quarter and by 14% YoY
The quick ratio has soared by 80% from the previous quarter and by 8% YoY
AGTC's debt has soared by 166% YoY
The revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of AGTC
Market
Shares outstanding
42.75M
Market cap
$142.8M
Enterprise value
$67.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$59.12M
EBITDA
-$57.23M
Free cash flow
-$52.62M
Per share
EPS
-$2.17
Free cash flow per share
-$1.43
Book value per share
$2.27
Revenue per share
$0
TBVPS
$3.49
Balance sheet
Total assets
$129.67M
Total liabilities
$32.67M
Debt
$14.59M
Equity
$97M
Working capital
$96.47M
Liquidity
Debt to equity
0.15
Current ratio
6.83
Quick ratio
6.71
Net debt/EBITDA
1.31
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.1%
Return on equity
-90.6%
Return on invested capital
-114.6%
Return on capital employed
-52.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGTC stock price

How has the Applied Genetic Technologies stock price performed over time
Intraday
2.45%
1 week
-1.47%
1 month
-2.34%
1 year
-34.12%
YTD
-18.34%
QTD
-14.58%

Financial performance

How have Applied Genetic Technologies's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.25M
Net income
-$60.2M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
Applied Genetic Technologies's gross profit has shrunk by 100% YoY
AGTC's net income is down by 44% year-on-year and by 6% since the previous quarter
Applied Genetic Technologies's operating income has decreased by 35% YoY and by 5% QoQ

Growth

What is Applied Genetic Technologies's growth rate over time

Valuation

What is Applied Genetic Technologies stock price valuation
P/E
N/A
P/B
1.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Applied Genetic Technologies's EPS has increased by 4.4% QoQ
Applied Genetic Technologies's equity has soared by 134% from the previous quarter and by 14% YoY
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 2.3 but 23% more than its 5-year quarterly average of 1.2
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Applied Genetic Technologies business performance
AGTC's ROE has plunged by 58% YoY
AGTC's ROIC is down by 44% YoY and by 6% QoQ
AGTC's return on assets is down by 35% year-on-year

Dividends

What is AGTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGTC.

Financial health

How did Applied Genetic Technologies financials performed over time
AGTC's total assets has soared by 80% QoQ and by 23% YoY
The quick ratio has soared by 80% from the previous quarter and by 8% YoY
AGTC's debt is 85% less than its equity
AGTC's debt has soared by 166% YoY
Applied Genetic Technologies's debt to equity has surged by 150% YoY but it has shrunk by 57% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.